76 related articles for article (PubMed ID: 3945117)
1. Directed intravascular precipitation of bisantrene for pelvic malignant lesions: preclinical studies.
Lieber MM; Welch TJ; Johnson CM; Farrow GM; Buck M; Kovach JS
Mayo Clin Proc; 1986 Mar; 61(3):173-9. PubMed ID: 3945117
[TBL] [Abstract][Full Text] [Related]
2. Regional targeting of bisantrene by directed intravascular precipitation.
Kovach JS; Buck M; Tsukamoto T; Odegaard A; Lieber MM
Cancer Chemother Pharmacol; 1985; 15(3):192-5. PubMed ID: 4053264
[TBL] [Abstract][Full Text] [Related]
3. Disposition of bisantrene in humans and rabbits: evidence for intravascular deposition of drug as a cause of phlebitis.
Powis G; Kovach JS
Cancer Res; 1983 Feb; 43(2):925-9. PubMed ID: 6848203
[TBL] [Abstract][Full Text] [Related]
4. Bisantrene solubility and skin toxicity studies: efficacy of sodium bicarbonate as a local ulceration antidote.
Dorr RT; Peng YM; Alberts DS
Invest New Drugs; 1984; 2(4):351-7. PubMed ID: 6096286
[TBL] [Abstract][Full Text] [Related]
5. Phase I clinical investigation of 9,10-anthracenedicarboxaldehyde bis[(4,5-dihydro-1H-imidazol-2-yl)hydrazone] dihydrochloride with correlative in vitro human tumor clonogenic assay.
Alberts DS; Mackel C; Pocelinko R; Salmon SE
Cancer Res; 1982 Mar; 42(3):1170-5. PubMed ID: 7037174
[TBL] [Abstract][Full Text] [Related]
6. Phase I clinical and pharmacokinetic study of bisantrene in refractory pediatric solid tumors.
Pratt CB; Sinkule JA; Etcubanas E; Douglass EC; Crom DB; Choi K; Avery L
Invest New Drugs; 1986; 4(2):149-53. PubMed ID: 3733375
[TBL] [Abstract][Full Text] [Related]
7. Blood and tissue concentrations of Bisantrene measured by a simple fluorometric assay.
Buck M; Kovach JS
Cancer Chemother Pharmacol; 1985; 15(1):40-3. PubMed ID: 4006048
[TBL] [Abstract][Full Text] [Related]
8. Bisantrene, biological and clinical effects.
Coltman CA; Osborne CK
Cancer Treat Rev; 1984 Dec; 11(4):285-8. PubMed ID: 6534510
[TBL] [Abstract][Full Text] [Related]
9. Randomized trial of doxorubicin, bisantrene, and mitoxantrone in advanced breast cancer: a Southwest Oncology Group study.
Cowan JD; Neidhart J; McClure S; Coltman CA; Gumbart C; Martino S; Hutchins LF; Stephens RL; Vaughan CB; Osborne CK
J Natl Cancer Inst; 1991 Aug; 83(15):1077-84. PubMed ID: 1875415
[TBL] [Abstract][Full Text] [Related]
10. Bisantrene, an active drug in patients with advanced breast cancer.
Osborne CK; Von Hoff DD; Cowan JD; Sandbach J
Cancer Treat Rep; 1984 Feb; 68(2):357-60. PubMed ID: 6697324
[TBL] [Abstract][Full Text] [Related]
11. Phase I clinical evaluation of 9,10-anthracenedicarboxyaldehyde[bis(4,5-dihydro-1H-imidazol-2-yl)hydrazone]dihydrochloride (bisantrene).
Yap BS; Yap HY; Blumenschein GR; Bedikian AY; Pocelinko R; Bodey GP
Cancer Treat Rep; 1982 Jul; 66(7):1517-20. PubMed ID: 7093967
[TBL] [Abstract][Full Text] [Related]
12. In vivo and in vitro metabolism of the new anticancer drug bisantrene.
Peng YM; Alberts DS; Davis TP
Cancer Chemother Pharmacol; 1985; 14(1):15-20. PubMed ID: 3965156
[TBL] [Abstract][Full Text] [Related]
13. Phase I study of bisantrene in acute nonlymphoblastic leukemia.
Marty M; Ferme C; Gisselbrecht C; Guy H; Clark MJ; Bancillon A; Boiron M
Cancer Treat Rep; 1985 Jun; 69(6):703-5. PubMed ID: 4016773
[TBL] [Abstract][Full Text] [Related]
14. Bisantrene in advanced, hormone-resistant carcinoma of the prostate: an Illinois Cancer Council phase II study.
Vogelzang NJ; Lanzotti VJ; Muntean B; Blough RR
Invest New Drugs; 1990 Aug; 8(3):313-5. PubMed ID: 2272771
[No Abstract] [Full Text] [Related]
15. Retroviral transfer of the human MDR1 gene confers resistance to bisantrene-specific hematotoxicity.
Aksentijevich I; Cardarelli CO; Pastan I; Gottesman MM
Clin Cancer Res; 1996 Jun; 2(6):973-80. PubMed ID: 9816258
[TBL] [Abstract][Full Text] [Related]
16. Intravascular streaming during carotid artery infusions. Demonstration in humans and reduction using diastole-phased pulsatile administration.
Saris SC; Blasberg RG; Carson RE; deVroom HL; Lutz R; Dedrick RL; Pettigrew K; Chang R; Doppman J; Wright DC
J Neurosurg; 1991 May; 74(5):763-72. PubMed ID: 1849555
[TBL] [Abstract][Full Text] [Related]
17. Activity of bisantrene in refractory lymphoma.
McLaughlin P; Cabanillas F; Hagemeister FB; Velasquez WS
Cancer Treat Rep; 1987 Jun; 71(6):631-3. PubMed ID: 3581102
[TBL] [Abstract][Full Text] [Related]
18. Anaphylactoid reactions associated with bisantrene infusions.
Myers JW; Von Hoff DD; Kuhn JG; Osborne CK; Sandbach JF; Pocelinko R
Invest New Drugs; 1983; 1(1):85-8. PubMed ID: 6678858
[TBL] [Abstract][Full Text] [Related]
19. Phase II trial of bisantrene in advanced colorectal carcinoma.
Ahmed T; Kemeny NE; Michaelson RA; Harper HD
Cancer Treat Rep; 1983 Mar; 67(3):307-8. PubMed ID: 6831479
[No Abstract] [Full Text] [Related]
20. [Complication after selective arterial embolization in internal iliac artery and median sacral artery with gelfoam particle in dogs].
Li Y; Yin Z; Wang W; Qin K; Wang Y
Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi; 2011 Jun; 25(6):724-8. PubMed ID: 21735788
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
